Ely Benaim's most recent trade in NovoCure Ltd was a trade of 98 Ordinary Shares done at an average price of $62.3 . Disclosure was reported to the exchange on Jan. 6, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 62.31 per share. | 06 Jan 2023 | 98 | 28,770 (0%) | 0% | 62.3 | 6,106 | Ordinary Shares |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 74.00 per share. | 03 Aug 2022 | 5,396 | 28,672 (0%) | 0% | 74 | 399,304 | Ordinary Shares |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 71.09 per share. | 03 Aug 2022 | 563 | 34,068 (0%) | 0% | 71.1 | 40,024 | Ordinary Shares |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 69.66 per share. | 02 Aug 2022 | 437 | 34,631 (0%) | 0% | 69.7 | 30,441 | Ordinary Shares |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 59.08 per share. | 05 Jul 2022 | 222 | 35,068 (0%) | 0% | 59.1 | 13,115 | Ordinary Shares |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 61.25 per share. | 10 May 2022 | 2,135 | 34,846 (0%) | 0% | 61.3 | 130,769 | Ordinary Shares |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 65.16 per share. | 10 May 2022 | 2,070 | 36,981 (0%) | 0% | 65.2 | 134,877 | Ordinary Shares |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 30,422 | 30,422 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 17,371 | 45,570 (0%) | 0% | 0 | Ordinary Shares | |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 5,452 | 5,452 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 70.41 per share. | 03 Mar 2022 | 1,510 | 43,257 (0%) | 0% | 70.4 | 106,315 | Ordinary Shares |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 74.50 per share. | 03 Mar 2022 | 803 | 44,767 (0%) | 0% | 74.5 | 59,822 | Ordinary Shares |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 63.82 per share. | 06 Jan 2022 | 55 | 28,199 (0%) | 0% | 63.8 | 3,510 | Ordinary Shares |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 150.11 per share. | 03 Aug 2021 | 464 | 28,144 (0%) | 0% | 150.1 | 69,651 | Ordinary Shares |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 83.30 per share. | 30 Jul 2021 | 651 | 29,795 (0%) | 0% | 83.3 | 54,228 | Ordinary Shares |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2021 | 651 | 3,253 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 158.96 per share. | 30 Jul 2021 | 651 | 29,144 (0%) | 0% | 159.0 | 103,483 | Ordinary Shares |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 149.38 per share. | 30 Jul 2021 | 536 | 28,608 (0%) | 0% | 149.4 | 80,067 | Ordinary Shares |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 137.12 per share. | 06 Jul 2021 | 90 | 29,144 (0%) | 0% | 137.1 | 12,341 | Ordinary Shares |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.56 per share. | 27 May 2021 | 1,833 | 30,887 (0%) | 0% | 47.6 | 87,177 | Ordinary Shares |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 May 2021 | 1,833 | 7,332 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 200.00 per share. | 27 May 2021 | 1,833 | 29,054 (0%) | 0% | 200 | 366,600 | Ordinary Shares |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 180.48 per share. | 12 May 2021 | 1,943 | 29,054 (0%) | 0% | 180.5 | 350,673 | Ordinary Shares |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 180.12 per share. | 10 May 2021 | 2,262 | 30,997 (0%) | 0% | 180.1 | 407,427 | Ordinary Shares |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.56 per share. | 10 May 2021 | 1,833 | 35,092 (0%) | 0% | 47.6 | 87,177 | Ordinary Shares |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 May 2021 | 1,833 | 9,165 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 189.65 per share. | 10 May 2021 | 1,833 | 33,259 (0%) | 0% | 189.6 | 347,628 | Ordinary Shares |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2021 | 3,474 | 19,404 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 200.00 per share. | 13 Apr 2021 | 3,474 | 33,259 (0%) | 0% | 200 | 694,800 | Ordinary Shares |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 69.37 per share. | 13 Apr 2021 | 3,474 | 36,733 (0%) | 0% | 69.4 | 240,991 | Ordinary Shares |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 200.00 per share. | 13 Apr 2021 | 1,833 | 33,259 (0%) | 0% | 200 | 366,600 | Ordinary Shares |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.56 per share. | 13 Apr 2021 | 1,833 | 35,092 (0%) | 0% | 47.6 | 87,177 | Ordinary Shares |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2021 | 1,833 | 10,998 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2021 | 651 | 3,904 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 200.00 per share. | 13 Apr 2021 | 651 | 33,259 (0%) | 0% | 200 | 130,200 | Ordinary Shares |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 83.30 per share. | 13 Apr 2021 | 651 | 33,910 (0%) | 0% | 83.3 | 54,228 | Ordinary Shares |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 131.53 per share. | 05 Mar 2021 | 2,918 | 33,259 (0%) | 0% | 131.5 | 383,805 | Ordinary Shares |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 150.78 per share. | 03 Mar 2021 | 3,475 | 38,065 (0%) | 0% | 150.8 | 523,961 | Ordinary Shares |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2021 | 3,475 | 22,878 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 69.37 per share. | 03 Mar 2021 | 3,475 | 41,540 (0%) | 0% | 69.4 | 241,061 | Ordinary Shares |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 137.55 per share. | 03 Mar 2021 | 1,888 | 36,177 | - | 137.6 | 259,702 | Restricted Share Units |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 16,003 | 16,003 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 8,709 | 38,065 | - | 0 | Restricted Share Units | |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2020 | 1,833 | 12,831 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.56 per share. | 21 Dec 2020 | 1,833 | 31,189 (0%) | 0% | 47.6 | 87,177 | Ordinary Shares |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 156.71 per share. | 21 Dec 2020 | 1,833 | 29,356 (0%) | 0% | 156.7 | 287,249 | Ordinary Shares |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 156.71 per share. | 21 Dec 2020 | 651 | 29,356 (0%) | 0% | 156.7 | 102,018 | Ordinary Shares |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2020 | 651 | 4,555 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 83.30 per share. | 21 Dec 2020 | 651 | 30,007 (0%) | 0% | 83.3 | 54,228 | Ordinary Shares |
| NovoCure Ltd | Ely Benaim | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 76.06 per share. | 03 Aug 2020 | 660 | 29,356 (0%) | 0% | 76.1 | 50,200 | Ordinary Shares |